A Phase 3 interventional study of Maintenance in Wet Age-related Macular Degeneration (wAMD), sponsored by Clinique de Retine de l'est. Not yet recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-19.
Sponsored by Clinique de Retine de l'est · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 94 studies in Macular Degeneration with a site in Canada — 11 open to participants now, 16 under way, 7 of them phase 3. Macular Degeneration · Canada.
Among the 94 studies in Macular Degeneration with a site in Canada, this one is the 38th largest by planned enrollment of the 77 interventional ones that give a count, is one of 7 that started in 2025, is one of 28 in phase 3, reaches primary completion later than 5 of the 15 other live ones, and was the 92nd registered.
1,461 studies on the registry are indexed under Macular Degeneration; 237 are open to participants now.
Browse Macular Degeneration studies →11 of the 94 studies in Macular Degeneration with a site in Canada are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in Canada, United States, Argentina and 16 more countries
Ages 50+
ADARx Pharmaceuticals, Inc. · Sites in Canada, United States, Australia and 9 more countries
Ages 60+
AbbVie · Sites in Canada, United States, Austria and 14 more countries
Ages 50+
ONL Therapeutics · Sites in Canada, United States, Austria and 9 more countries
Ages 55+
Kriya Therapeutics, Inc. · Sites in Canada, United States, Israel and 1 more country
Ages 55–80
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 167 Macular Degeneration studies recruiting now, 118 (71%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
94 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 20 · Phase 3 31 · Phase 4 11
First in 1999; this study’s year is marked. 7 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 180 is above the median of 56 across 986 interventional studies indexed under Macular Degeneration.
Median enrollment 180 across the 77 interventional studies, 169 across the 17 observational. Of the 63 that completed or were terminated, 26 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
55 of 94 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Clinique de Retine de l'est as lead sponsor.
Clinique de Retine de l'est has 1 study filed under Macular Degeneration — fewer than ten, so there is no comparison to draw.
5 of the studies in Macular Degeneration with a site in Canada that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07129239Phase 3Clinique de Retine de l'estHigh Dose (HD) Aflibercept Switch in Neovascular Age-related Macular Degeneration (nAMD): to Load or Maintain (HEIRLOOM) | 2027-02 |
| NCT06864988Phase 34D Molecular Therapeutics4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration | 2027-06 |
| NCT05904028Phase 3Jaeb Center for Health ResearchHome OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD | 2027-07-30 |
| NCT04762368University of WaterlooLearning Study: Improving Vision in Adults With Macular Degeneration | 2026-12 |
| NCT07917715Clarity Eye InstituteMacuMira Microcurrent Stimulation for Dark Adaptation in Dry Age-Related Macular Degeneration | 2027-08-16 |
Add all 5 to your calendar (.ics) → With an account.
Among the 94 studies in Macular Degeneration with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare two treatment frequencies using EYLEA® HD (aflibercept 8mg) in patients with wet age-related macular degeneration (wAMD) that are currently treated with EYLEA® (aflibercept 2mg).
EYLEA® HD is approved by Health Canada has been tested in large clinical trials involving thousands of patients around the world and has been shown effective in the treatment of wAMD. The treatment regimen used in these trials involved 3 initial monthly injections of EYLEA® HD followed by an extension of the treatment interval on the 4th visit. This was necessary since all patients in this study did not previously have treatment injections for wAMD.
Currently there is not enough information on the best treatment regimen to use for patients that are switched to EYLEA® HD from EYLEA®.
Health Canada currently recommends that EYLEA® HD is administered every month for the first 3 doses, followed by a treatment every 8 to 16 weeks.
A total of 180 patients >18 years of age will participate in this study, which will be conducted at the Clinique de Retine de l'Est in Montreal, Quebec, Canada.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
patients who are currently being treated with EYLEA® (aflibercept 2mg) will be switched to EYLEA® HD (aflibercept 8mg) and receive injections every month for the first 3 months followed by an extension (or increase in dosing interval) of therapy based on clinical response. This is the "on label" treatment regimen approved by Health Canada.
patients who are currently being treated with EYLEA® (aflibercept 2mg) will be switched to EYLEA® HD (aflibercept 8mg) and maintain the current treatment interval that they had with EYLEA® (aflibercept 2mg), followed by an extension of therapy (or increase in treatment dosing interval) based on clinical response. This is the "off-label" treatment regimen that we are testing to see if it is as effective and involves less treatment burden.
Other: Maintenance
Patients who are currently being treated with EYLEA® (aflibercept 2mg) will be switched to EYLEA® HD (aflibercept 8mg) and maintain the current treatment interval that they had with EYLEA® (aflibercept 2mg), followed by an extension of therapy (or increase in treatment dosing interval) based on clinical response
Central Retinal Thickness (CRT)
The primary endpoint will derived from Optical Coherence Tomography (OCT), in µm and measured at 12 months after switching therapies with interim analysis at 6 months (Detected on 8 line radial scans, through the fovea).
Time frame: 6 and 12 month
Visual Acuity
Visual acuity measured by the Snellen method and then converted to Early Treatment Diabetic Retinopathy Study (EDTRS) letters. Change in visual acuity will be assessed at 6 and 12 months compared to baseline.
Time frame: 6 and 12 month
Number of injections
duration between last injection at 6 months and 12 months from date of the switch measured
Time frame: 6 and 12 month
Adverse events
Will be reported at 6 and 12 months from date of the switch measured by frequency of events (numerical), as well as descriptive for what type of adverse event.
Time frame: 6 and 12 month
Presence of Subretinal Fluid (Yes/No)
This measure will be derived from Optical Coherence Tomography (OCT), and measured at 12 months after switching therapies with interim analysis at 6 months (Detected on 8 line radial scans, through the fovea).
Time frame: 6 months and 12 months
Presence of Intraretinal Fluid (Yes/No)
This measure will be derived from Optical Coherence Tomography (OCT), and measured at 12 months after switching therapies with interim analysis at 6 months (Detected on 8 line radial scans, through the fovea).
Time frame: 6 months and 12 months
Pigment Epithelial Detachment (PED) Type
Morphology and type of PED will be derived from Optical Coherence Tomography (OCT), and measured at 12 months after switching therapies with interim analysis at 6 months (Detected on 8 line radial scans, through the fovea).
Time frame: 6 months and 12 months
Pigment Epithelial Detachment (PED) Height
This outcome measure will be derived from Optical Coherence Tomography (OCT), measured in um, and measured at 12 months after switching therapies with interim analysis at 6 months (Detected on 8 line radial scans, through the fovea).
Time frame: 6 months and 12 months
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Aug 2025; primary completion for Feb 2027, 18 months later.
Of 83 phase 3 interventional studies under Macular Degeneration, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 35. This study's planned 18 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.